Tenet is a clinical intelligence company. We take what is true about a place, who lives there, how they get to care, what else is competing for them, and turn it into a specific statement about a specific trial: this site will enroll, this one will stall, and here is why.
A trial does not usually fail because of what happens inside the building. Site selection today is a judgement about buildings. The patient does not care about the building. They care whether they can get there and whether anyone told them the trial exists. A snapshot of a site is good for the day it was taken. Tenet reads the world instead of the building, and keeps reading it. Reaching the people who actually have the disease is not a values statement. It is how the trial finishes.
It is built to say nothing. The most important component decides whether a signal reaches a reader at all; the bar is whether a sponsor would act differently because of it. The default is silence. And we publish what does not work, including an accuracy claim we corrected downward ourselves. That is the reason to believe the numbers that survived.
Our family has run clinical research for sponsors since 2002. The read Tenet makes is the one our family has made for two decades, and the one every good operator makes in their head. When one of the largest life sciences companies in the world brought us a trial design and asked whether it would work, the answer was no, and the reason was not the science. It was the world around the sites, and what the protocol asked of the people who actually have the condition. Tenet is that judgement, made on every site, every day, and scored.
The network behind it reaches the executive teams of some of the largest device, pharma and distribution companies in the country. The family works regularly with the FDA and holds federal contracts we can scale into. And the industry is relocating to Texas, where we already are. The platform is in production; a medical device sponsor and a site network are evaluating it today.